08:13 AM EDT, 10/27/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Monday that icotrokinra demonstrated sustained and clinically meaningful results in certain adults with ulcerative colitis at week 28 of the phase 2b ANTHEM-UC study.

All tested doses of icotrokinra showed higher rates of clinical response, clinical remission, endoscopic improvement and histologic-endoscopic mucosal improvement compared to placebo, the company said.

Based on these results, Johnson & Johnson ( JNJ ) said it has initiated the ICONIC-UC phase 3 protocol in adults and adolescents with moderately to severely active ulcerative colitis, as well as the ICONIC-CD phase 2b/3 protocol in adults with moderate to severely active Crohn's disease.